Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

(2020) Shiying Shao et al.   PHARMACOLOGY & THERAPEUTICS

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

(2020) Furong Qi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

(2020) Lihua Zhu et al.   Cell Metabolism

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

(2020) Yuchen Chen et al.   DIABETES CARE

Exposure to DPP ‐4 inhibitors and COVID ‐19 among people with type 2 diabetes. A case–control study

(2020) Gian Paolo Fadini et al.   DIABETES OBESITY & METABOLISM

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

(2020) Bertrand Cariou et al.   DIABETOLOGIA

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies

(2020) Alessandro Mantovani et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Prevalence and impact of diabetes among people infected with SARS-CoV-2

(2020) G. P. Fadini et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

COVID-19 cytokine storm: the interplay between inflammation and coagulation

(2020) Ricardo J Jose et al.   Lancet Respiratory Medicine

The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control

(2020) Yosra A. Helmy et al.   Journal of Clinical Medicine

COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?

(2020) T. Filardi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study

(2020) Rinkoo Dalan et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory

(2020) Enzo Bonora et al.   BMJ Open Diabetes Research & Care

Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID‐19: A Large Case‐Control Study

(2020) Huadong Yan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

(2020) Sebastiano Bruno Solerte et al.   DIABETES CARE

Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy

(2020) Marco Mirani et al.   DIABETES CARE

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

(2020) Michael A. Nauck et al.   DIABETES CARE

Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID ‐19: A population‐based retrospective cohort study

(2020) Christopher Sainsbury et al.   DIABETES OBESITY & METABOLISM

Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily

(2020) Silverii Giovanni Antonio et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory

(2020) Enzo Bonora et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

(2020) Luis M. Pérez-Belmonte et al.   BMC Medicine

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2

(2020) Cecy R Xi et al.   MOLECULES

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus

(2019) Giorgio Sesti et al.   ACTA DIABETOLOGICA

Real-world studies no substitute for RCTs in establishing efficacy

(2019) Hertzel C Gerstein et al.   LANCET

Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy

(2018) E. Bonora et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice

(2018) Takeshi Kawasaki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

(2016) Lucie Sromova et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence

(2015) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

(2013) Tatsuhiko Saito et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

(2013) Guangwen Lu et al.   NATURE

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Sitagliptin Exerts an Antinflammatory Action

(2012) Antoine Makdissi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM